Relmada Therapeutics, Inc. (RLMD) News https://www.relmada.com/for-investors/news/rss en-us https://d1io3yog0oux5.cloudfront.net/relmada/files/theme/images/logo-sm.png Relmada Therapeutics, Inc. Logo /for-investors Equisolve Investor Relations Suite <![CDATA[Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update]]> https://www.relmada.com/for-investors/news/detail/336/relmada-therapeutics-reports-fourth-quarter-and-full-year Thu, 19 Mar 26 16:01:00 -0400 https://www.relmada.com/for-investors/news/detail/336/relmada-therapeutics-reports-fourth-quarter-and-full-year <![CDATA[Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026]]> https://www.relmada.com/for-investors/news/detail/335/relmada-therapeutics-to-report-fourth-quarter-2025 Thu, 12 Mar 26 07:00:00 -0400 https://www.relmada.com/for-investors/news/detail/335/relmada-therapeutics-to-report-fourth-quarter-2025 <![CDATA[Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference]]> https://www.relmada.com/for-investors/news/detail/334/relmada-therapeutics-to-present-at-the-leerink-partners Mon, 09 Mar 26 16:30:00 -0400 https://www.relmada.com/for-investors/news/detail/334/relmada-therapeutics-to-present-at-the-leerink-partners <![CDATA[Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing]]> https://www.relmada.com/for-investors/news/detail/333/relmada-therapeutics-announces-oversubscribed-160-0 Mon, 09 Mar 26 07:05:00 -0400 https://www.relmada.com/for-investors/news/detail/333/relmada-therapeutics-announces-oversubscribed-160-0 <![CDATA[Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer]]> https://www.relmada.com/for-investors/news/detail/332/relmada-therapeutics-reports-12-month-phase-2-interim-data Mon, 09 Mar 26 07:00:00 -0400 https://www.relmada.com/for-investors/news/detail/332/relmada-therapeutics-reports-12-month-phase-2-interim-data <![CDATA[Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications]]> https://www.relmada.com/for-investors/news/detail/331/relmada-therapeutics-provides-regulatory-update-confirming Mon, 12 Jan 26 07:00:00 -0500 https://www.relmada.com/for-investors/news/detail/331/relmada-therapeutics-provides-regulatory-update-confirming <![CDATA[Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology]]> https://www.relmada.com/for-investors/news/detail/330/relmada-therapeutics-announces-presentation-of-ndv-01-phase Wed, 03 Dec 25 07:30:00 -0500 https://www.relmada.com/for-investors/news/detail/330/relmada-therapeutics-announces-presentation-of-ndv-01-phase <![CDATA[Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates]]> https://www.relmada.com/for-investors/news/detail/329/relmada-therapeutics-reports-third-quarter-2025-financial Thu, 13 Nov 25 16:01:00 -0500 https://www.relmada.com/for-investors/news/detail/329/relmada-therapeutics-reports-third-quarter-2025-financial <![CDATA[Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025]]> https://www.relmada.com/for-investors/news/detail/328/relmada-therapeutics-to-report-third-quarter-2025-financial Fri, 07 Nov 25 07:30:00 -0500 https://www.relmada.com/for-investors/news/detail/328/relmada-therapeutics-to-report-third-quarter-2025-financial <![CDATA[Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants]]> https://www.relmada.com/for-investors/news/detail/327/relmada-therapeutics-announces-pricing-of-100-million Tue, 04 Nov 25 07:09:00 -0500 https://www.relmada.com/for-investors/news/detail/327/relmada-therapeutics-announces-pricing-of-100-million